Related Experiment Videos
Juvenile parkinsonism: a heterogeneous entity
1Movement Disorders Clinic, Department of Neurology, The Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. cardosof@metalink.com.br
Insights
Juvenile Parkinsonism (JP) presents heterogeneously, often without a clear cause, and typically progresses rapidly. While L-dopa offers some benefit, many patients develop complications, highlighting the need for further research into this rare condition.
Area of Science:
- Neurology
- Pediatric Neurology
- Neurodegenerative Diseases
Background:
- Juvenile Parkinsonism (JP) is defined as Parkinsonism with onset before age 20.
- Understanding the clinical spectrum and natural history of JP is crucial for diagnosis and management.
- This study investigates a cohort of JP patients to characterize their disease course.
Observation:
- Six patients (five male, one female) with JP were studied, with a mean onset age of 12.5 years.
- Common symptoms included bradykinesia, rigidity, postural instability, and tremor; dystonia, dementia, and ophthalmoparesis were also observed.
- Neuroimaging revealed atrophy in some patients, and Wilson's disease was ruled out.
Findings:
- All patients showed L-dopa responsiveness, but four developed motor complications (fluctuations, dyskinesias) requiring intervention.
- After a mean of 6.5 years, five patients needed assistance with daily activities, indicating rapid progression.
- No specific cause was identified in most patients, suggesting a primary CNS degenerative process distinct from Parkinson's disease (PD) or gangliosidosis.
Implications:
- JP is a complex and heterogeneous condition, often presenting with atypical features.
- The rapid progression and L-dopa responsiveness in some cases suggest specific underlying pathologies.
- Further research is needed to identify the causes of JP and develop targeted therapies.
Abstract:
We studied the clinical features, laboratory investigation, management and natural history of a cohort of patients with Juvenile Parkinsonism (JP), seen at a tertiary referral centre. JP was defined as Parkinsonism with onset at age 20 years or less. Six patients (five male, one female) entered the study. The mean age at onset of Parkinsonism was 12.5 years (range 7-19) and the mean follow-up time was 49.3 months (range 40-57). Bradykinesia, rigidity, and postural instability were observed in all patients and five subjects had tremor. Dystonia was present in four subjects. Other clinical features were dementia (five subjects), supranuclear ophthalmoparesis (five subjects), seizures (three subjects), multifocal myoclonus (one subject), decreased deep reflexes (one subject), pyramidal signs (one subject). Family history of Parkinson's disease (PD) was positive in one subject. Work-up for Wilson's disease was negative in all patients. Neuroimaging studies showed cortical atrophy in two subjects and mild brainstem atrophy in two others. Sea-blue histiocytes were found in one subject. L-dopa improved the Parkinsonism in all subjects but four rapidly developed fluctuations and dyskinesias, requiring, in one, stereotaxic surgery. After a mean disease duration of 6.5 years, five subjects require assistance for performance of all daily activities. JP is a heterogeneous clinical entity. In the majority of patients, no underlying cause is identified. The unusual clinical features suggest most subjects have a CNS degenerative disease distinct from PD. There is, however, evidence suggesting that PD may rarely cause JP. Gangliosidosis is another cause of L-dopa-responsive JP. Regardless of the cause, in the present study JP displays an aggressive and rapidly progressive course in most patients.